Losartan Cost in Indiana (2026): Cash Price, Medicaid, Insurance, and Discount Options

Losartan, sold under the brand name Cozaar, is an oral medication that blocks angiotensin II receptors and is approved to treat high blood pressure, kidney damage from type 2 diabetes, and to reduce stroke risk in patients with thickened heart muscle. Since becoming available as a generic medication in 2010, losartan ranks among the most affordable blood pressure medications available by prescription in the United States and Indiana. Because out-of-pocket costs, Medicaid authorization requirements, and insurance copayments vary by location and pharmacy and may shift over time, this article distinguishes information that remains constant and is documented at the federal level from details you should confirm with your local pharmacy or insurance plan before obtaining losartan.

This draft is pending qualified clinical and pharmacy-benefit review before publication.

The short answer

Generic losartan tablets are widely available at low cost through Indiana retail and mail-order pharmacies, commonly cited in the low double digits per month for cash-paying patients, though the exact figure at any given pharmacy on any given day requires direct verification. Indiana Medicaid coverage rules for losartan are set by the state's preferred drug list and change periodically; a reader should confirm current coverage terms with the Indiana Health Coverage Programs or their managed-care plan rather than relying on a number printed here. Compounded losartan is legally available through Indiana-licensed 503A pharmacies when a patient has a documented clinical need a commercial tablet cannot meet, per FDA compounding rules.

What's established versus what needs local verification

Established and stable (federal or clinical facts that don't change by ZIP code or by month):

• Losartan is FDA-approved for hypertension, diabetic nephropathy associated with type 2 diabetes, and stroke-risk reduction in patients with hypertension and left ventricular hypertrophy, per the FDA-approved prescribing information.
• Losartan is prescription-only in every U.S. state, including Indiana. There is no over-the-counter version.
• Generic losartan tablets have been available from multiple manufacturers since patent expiration in 2010, which is the main structural reason its price is low compared with newer antihypertensives.
• Compounding of losartan by a licensed 503A pharmacy, with a patient-specific prescription, is legal and distinct from mass production by a 503B outsourcing facility, per FDA guidance on compounding.
• Baseline and follow-up monitoring of potassium and kidney function is standard practice when starting or adjusting an ARB, consistent with the drug label's precautions.

Date-sensitive and locality-specific (verify before quoting to a patient):

• The exact cash price for a 30-day or 90-day supply at any specific Indiana pharmacy chain or independent pharmacy.
• Whether a specific Indiana Medicaid managed-care plan (currently Anthem, CareSource, and MHS administer Healthy Indiana Plan benefits) requires a prior authorization for losartan, and for which diagnosis codes.
• Whether a discount card or manufacturer copay program is currently active and what its terms are.
• Whether a particular commercial or Medicare Part D formulary places losartan on a $0 or low-copay generic tier this plan year.
• Whether a specific compounding pharmacy in Indiana currently compounds losartan, and at what price.

Indiana Medicaid coverage: what to confirm before assuming denial or approval

State Medicaid preferred drug lists change on a regular cycle, and coverage for a generic ARB like losartan can differ depending on whether the diagnosis is hypertension alone versus diabetic nephropathy, and depending on which managed-care entity administers the patient's Healthy Indiana Plan benefit. A clinical rationale exists for prioritizing ARBs in patients with type 2 diabetes and albuminuria, since renin-angiotensin-system blockade is a guideline-supported approach in that population; but the specific prior-authorization criteria, diagnosis-code requirements, and approval rates for an individual Indiana Medicaid plan are administrative details that change and must be confirmed directly with the Indiana Health Coverage Programs or the relevant managed-care plan rather than assumed from a general article. If a patient is prescribed losartan for hypertension alone and a Medicaid claim is denied, the prescriber can typically appeal or document why an ACE inhibitor is not appropriate (for example, ACE-inhibitor cough or angioedema history), but the specific approval pathway and expected turnaround should come from the plan, not from this page.

Insurance coverage beyond Medicaid

Because losartan is a mature, multisource generic, most commercial insurance formularies, Medicare Part D plans, and ACA marketplace plans place it on their lowest generic tier, which typically means a modest flat copay rather than coinsurance. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs, in effect since 2025, is a real federal policy, but it is far more relevant to expensive brand-name drugs than to a low-cost generic like losartan, so most Medicare patients taking only losartan will not come close to that cap from this drug alone. Readers should still check their own plan's current formulary tier and copay for losartan each plan year, since tier placement is reset annually and can change.

Verification checklist: what to confirm before quoting a losartan cost or coverage answer

Use this checklist before telling a patient a specific number. Items in the first group are stable and rarely need re-checking. Items in the second group expire and must be re-verified at the point of care.

Stable facts (verify once, rarely changes):

• Confirm losartan's three FDA-approved indications on the current label (hypertension, diabetic nephropathy in T2D, stroke-risk reduction with LVH)
• Confirm losartan is prescription-only with no OTC pathway
• Confirm generic availability status (generic since 2010, multiple manufacturers)
• Confirm the distinction between 503A patient-specific compounding and 503B outsourcing-facility production

Date-sensitive facts (re-verify at time of use, cite the date you checked):

• Call or check the website of the specific Indiana pharmacy (chain or independent) for that day's cash price
• Check the patient's specific Indiana Medicaid managed-care plan (Anthem, CareSource, or MHS) for current losartan PA rules and diagnosis-code requirements
• Check the patient's specific commercial or Part D plan formulary and tier for the current plan year
• Confirm whether a discount card (for example GoodRx or SingleCare) or a manufacturer/authorized-generic copay program is currently active and what restrictions apply
• Confirm the specific compounding pharmacy is currently licensed by the Indiana Board of Pharmacy and currently compounds losartan, and get a direct price quote rather than relying on a published range
• Note the date each of the above was checked, since insurer and pharmacy pricing information can change month to month

Compounded losartan in Indiana

Compounded losartan (for example, an oral liquid suspension for a patient who cannot swallow tablets, or a formulation without a specific inactive ingredient a patient reacts to) is legal in Indiana when dispensed by a 503A pharmacy licensed by the Indiana Board of Pharmacy, with a valid patient-specific prescription, under FDA's compounding framework. Compounded preparations are not FDA-approved products; they are made under state pharmacy-board oversight for patients whose clinical needs cannot be met by a commercially available tablet. Pricing for compounded losartan varies by pharmacy, concentration, and volume, and no single statewide price applies. A patient considering a compounded product should verify the pharmacy's current license through the Indiana Professional Licensing Agency and get a direct quote, since compounded-drug pricing is not standardized the way generic tablet pricing tends to be.

Telehealth prescribing of losartan in Indiana

Indiana law permits telehealth encounters, including audio-video visits, to establish a prescriber-patient relationship and to prescribe non-controlled medications such as losartan, provided the prescriber performs an appropriate clinical evaluation. For an antihypertensive, that evaluation reasonably includes a blood pressure history (home readings are commonly accepted) and relevant lab values such as potassium and creatinine, particularly at initiation or after a dose change. Losartan is not a controlled substance, so Indiana's e-prescribing mandate for controlled substances does not apply to it; prescriptions can be sent electronically, by fax, or on paper to the pharmacy of the patient's choice. Specific platform availability and whether a given telehealth service currently prescribes to Indiana residents is a detail to confirm with that service directly.

Dosing basics that affect cost conversations, not individualized dosing advice

Losartan tablets are commonly available in 25 mg, 50 mg, and 100 mg strengths, with a typical adult starting dose around 25 to 50 mg once daily and a maximum labeled dose of 100 mg daily, taken once or split into two doses, per the FDA label. At most pharmacies using flat generic pricing, moving between strengths does not meaningfully change the cash price, and insurance copays are typically flat regardless of strength. This is general label information, not an individualized dosing recommendation; dose selection and titration should be determined by the prescribing clinician based on blood pressure response, kidney function, and potassium levels.

How losartan's price compares with other ARBs

Losartan is generally regarded as the least expensive ARB in its class because it was the first to lose patent protection and has the largest number of generic manufacturers. Other ARBs (valsartan, irbesartan, olmesartan, telmisartan, and azilsartan) are also available generically in most cases, with azilsartan generally remaining the most expensive due to more limited generic competition. Clinically, ARBs are broadly similar for blood-pressure lowering at equipotent doses; choice between them more often depends on comorbidity-specific trial evidence (for example, losartan's trial history in left ventricular hypertrophy and diabetic nephropathy, or other agents' trial history in heart failure), tolerability, and cost, rather than a meaningful difference in mechanism. Readers should treat any specific price comparison table between ARBs as a snapshot that requires re-verification, since generic pricing across a drug class shifts as manufacturers enter or exit the market.

Evidence used for clinical background in this article

Losartan's use in hypertension, diabetic nephropathy, and stroke-risk reduction in patients with left ventricular hypertrophy is documented on its FDA label. Randomized trial evidence supporting losartan in these populations, including the LIFE trial in patients with hypertension and left ventricular hypertrophy and the RENAAL trial in type 2 diabetic nephropathy, is well known in the cardiovascular and nephrology literature. This draft does not carry specific effect-size numbers (relative risk reductions, confidence intervals) from those trials forward without verification against the original publications, because the citation identifiers accompanying earlier versions of this page could not be confirmed as pointing to the correct papers. An editor with access to the primary Lancet and New England Journal of Medicine publications should confirm exact figures before they are republished with precision.

When to seek care rather than rely on this page

This article addresses cost and coverage, not individualized treatment decisions. A patient experiencing signs of a hypertensive emergency (severe headache, chest pain, shortness of breath, vision changes, or confusion with very high blood pressure readings) needs urgent medical evaluation rather than a pharmacy-price search. Anyone starting or adjusting losartan should follow their prescriber's monitoring plan, including baseline and follow-up potassium and kidney-function labs, and should not stop or change a blood-pressure medication based on cost concerns without talking to their prescriber, since untreated hypertension carries its own risks.